This is a paid press release. Contact the press release distributor directly with any inquiries.
Crescent Biopharma to Present at March Investor Conferences
Crescent Biopharma, Inc.
Mon, February 23, 2026 at 9:30 PM GMT+9 1 min read
In this article:
CBIO
-0.77%
Crescent Biopharma, Inc.
WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) – Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in March:
**TD Cowen 46****th**** Annual Health Care Conference, **fireside chat on Monday, March 2, 2026 at 3:50 p.m. ET in Boston.
**Leerink Partners 2026 Global Healthcare Conference, **fireside chat on Wednesday, March 11, 2026 at 8:40 a.m. ET in Miami.
A live webcast of each presentation will be available in the Investors section of Crescent’s website at and a replay will be accessible for 90 days.
About Crescent Biopharma
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Crescent Biopharma to Present at March Investor Conferences
This is a paid press release. Contact the press release distributor directly with any inquiries.
Crescent Biopharma to Present at March Investor Conferences
Crescent Biopharma, Inc.
Mon, February 23, 2026 at 9:30 PM GMT+9 1 min read
In this article:
CBIO
-0.77%
Crescent Biopharma, Inc.
WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) – Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in March:
A live webcast of each presentation will be available in the Investors section of Crescent’s website at and a replay will be accessible for 90 days.
About Crescent Biopharma
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.
Contact
Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586
Terms and Privacy Policy
Privacy Dashboard
More Info